Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.

Published Date: 14 Jun 2023

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells lacking in DNA damage repair, according to a recent study that appeared in Oncotarget.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Many patients learn they could have cancer in the emergency department

2.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

3.

The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

4.

A novel blood test may enable the early identification of common, fatal cancers.

5.

New drug combination shows good results in patients with HPV-negative head and neck cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot